Literature DB >> 23035982

Cognitive function after several years of antiretroviral therapy with stable central nervous system penetration score.

Y Kahouadji1, J Dumurgier, P Sellier, P Lapalus, V Delcey, Jf Bergmann, J Hugon, C Paquet.   

Abstract

OBJECTIVES: Previous studies in HIV-infected populations have yielded conflicting results on the effect of antiretroviral therapy (ART) on cognition. Our objective was to investigate the effect of several years of ART with stable central nervous system penetration effectiveness (CPE) score on neuropsychological performance in HIV-infected individuals.
METHODS: We analysed a clinical cohort of HIV-infected patients who initiated ART between June 2003 and December 2006 and maintained stable CPE scores. Patients were evaluated with a short neuropsychological battery. Using linear regression, we examined the relationship between results of cognitive tests and CPE scores in all patients.
RESULTS: Patients were divided into three similarly sized groups (CPE ≤ 1, CPE between 1.5 and 2.5, and CPE ≥ 2.5). We found that ART with high CPE scores was associated with poorer executive performances in HIV-1-infected patients.
CONCLUSION: These results suggest that cognitive performance in treated HIV-infected patients could be influenced by ART.
© 2012 British HIV Association.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23035982     DOI: 10.1111/j.1468-1293.2012.01052.x

Source DB:  PubMed          Journal:  HIV Med        ISSN: 1464-2662            Impact factor:   3.180


  17 in total

1.  The Effect of Central Nervous System Penetration Effectiveness of Highly Active Antiretroviral Therapy on Neuropsychological Performance and Neuroimaging in HIV Infected Individuals.

Authors:  Laurie M Baker; Robert H Paul; Jodi M Heaps-Woodruff; Jee Yoon Chang; Mario Ortega; Zachary Margolin; Christina Usher; Brian Basco; Sarah Cooley; Beau M Ances
Journal:  J Neuroimmune Pharmacol       Date:  2015-04-22       Impact factor: 4.147

2.  Pattern of neurocognitive function in patients receiving boosted protease inhibitor monotherapy: a detailed neuropsychological study.

Authors:  Alicia González-Baeza; Fernando Carvajal; Carmen Bayón; Ignacio Pérez-Valero; Miriam Estébanez; Jose I Bernardino; Susana Monge; María Lagarde; Asunción Hernando; Francisco Arnalich; José R Arribas
Journal:  J Neurovirol       Date:  2014-04-24       Impact factor: 2.643

3.  Altered Oligodendrocyte Maturation and Myelin Maintenance: The Role of Antiretrovirals in HIV-Associated Neurocognitive Disorders.

Authors:  Brigid K Jensen; Hubert Monnerie; Maggie V Mannell; Patrick J Gannon; Cagla Akay Espinoza; Michelle A Erickson; Annadora J Bruce-Keller; Benjamin B Gelman; Lisa A Briand; R Christopher Pierce; Kelly L Jordan-Sciutto; Judith B Grinspan
Journal:  J Neuropathol Exp Neurol       Date:  2015-11       Impact factor: 3.685

Review 4.  Neuropsychiatric Effects of HIV Antiviral Medications.

Authors:  Glenn J Treisman; Olivia Soudry
Journal:  Drug Saf       Date:  2016-10       Impact factor: 5.606

5.  HIV Protease Inhibitors Alter Amyloid Precursor Protein Processing via β-Site Amyloid Precursor Protein Cleaving Enzyme-1 Translational Up-Regulation.

Authors:  Patrick J Gannon; Cagla Akay-Espinoza; Alan C Yee; Lisa A Briand; Michelle A Erickson; Benjamin B Gelman; Yan Gao; Norman J Haughey; M Christine Zink; Janice E Clements; Nicholas S Kim; Gabriel Van De Walle; Brigid K Jensen; Robert Vassar; R Christopher Pierce; Alexander J Gill; Dennis L Kolson; J Alan Diehl; Joseph L Mankowski; Kelly L Jordan-Sciutto
Journal:  Am J Pathol       Date:  2017-01       Impact factor: 4.307

Review 6.  Genetic, transcriptomic, and epigenetic studies of HIV-associated neurocognitive disorder.

Authors:  Andrew J Levine; Stella E Panos; Steve Horvath
Journal:  J Acquir Immune Defic Syndr       Date:  2014-04-01       Impact factor: 3.731

7.  Topographies of Cortical and Subcortical Volume Loss in HIV and Aging in the cART Era.

Authors:  Anika Guha; Matthew R Brier; Mario Ortega; Elizabeth Westerhaus; Brittany Nelson; Beau M Ances
Journal:  J Acquir Immune Defic Syndr       Date:  2016-12-01       Impact factor: 3.731

Review 8.  Pharmacokinetics and pharmacodynamics of antiretrovirals in the central nervous system.

Authors:  Andrea Calcagno; Giovanni Di Perri; Stefano Bonora
Journal:  Clin Pharmacokinet       Date:  2014-10       Impact factor: 6.447

Review 9.  Clinical Treatment Options and Randomized Clinical Trials for Neurocognitive Complications of HIV Infection: Combination Antiretroviral Therapy, Central Nervous System Penetration Effectiveness, and Adjuvants.

Authors:  Shih-Ping Lin; Andrea Calcagno; Scott L Letendre; Qing Ma
Journal:  Curr Top Behav Neurosci       Date:  2021

Review 10.  Beneficial and Adverse Effects of cART Affect Neurocognitive Function in HIV-1 Infection: Balancing Viral Suppression against Neuronal Stress and Injury.

Authors:  Nina Y Yuan; Marcus Kaul
Journal:  J Neuroimmune Pharmacol       Date:  2019-08-06       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.